Literature DB >> 8118036

DNA rearrangements proximal to the EVI1 locus associated with the 3q21q26 syndrome.

E R Levy1, E Parganas, K Morishita, S Fichelson, L James, D Oscier, S Gisselbrecht, J N Ihle, V J Buckle.   

Abstract

Specific rearrangements involving 3q21 and 3q26 are well documented in acute myeloid leukemia (AML). Aberrant expression of the Ecotropic virus integration-1 (EVI1) gene, located at 3q26, has been reported in individuals with AML and translocations or inversions of chromosome 3 long arm. We have studied six individuals with AML and inv(3)(q21q26) for disruptions to the EVI1 locus by in situ hybridization and long-range mapping. EVI1 transcripts have been detected in the blast cells of the two individuals available for expression studies. We derived a YAC containing the EVI1 gene and showed that it crossed the 3q26 inversion breakpoints in three of four cases examined. Pulsed field analysis detected aberrant fragments 3' of the EVI1 gene in all six patients. The orientation of the gene was established and the locations of the breakpoints were refined by in situ hybridization using phage clones from this region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8118036

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.

Authors:  Kathryn E Boyd; Ying-Yi Xiao; Kai Fan; Amanda Poholek; Neal G Copeland; Nancy A Jenkins; Archibald S Perkins
Journal:  Blood       Date:  2005-10-04       Impact factor: 22.113

2.  PR-domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cell function.

Authors:  Yi Zhang; Sandra Stehling-Sun; Kimberly Lezon-Geyda; Subhash C Juneja; Lucie Coillard; Gouri Chatterjee; Charles A Wuertzer; Fernando Camargo; Archibald S Perkins
Journal:  Blood       Date:  2011-06-10       Impact factor: 22.113

3.  The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.

Authors:  M Kurokawa; K Mitani; T Yamagata; T Takahashi; K Izutsu; S Ogawa; T Moriguchi; E Nishida; Y Yazaki; H Hirai
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

4.  Molecular cytogenetic analyses of HIG, a novel human cell line carrying t(1;3)(p36.3;q25.3) established from a patient with chronic myelogenous leukemia in blastic crisis.

Authors:  Noriko Hosoya; Seishi Ogawa; Tohru Motokura; Akira Hangaishi; Lili Wang; Ying Qiao; Yasuhito Nannya; Mieko Kogi; Hisamaru Hirai
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

5.  EVI1 splice variants modulate functional responses in ovarian cancer cells.

Authors:  Punashi Dutta; Tuyen Bui; Kyle A Bauckman; Khandan Keyomarsi; Gordon B Mills; Meera Nanjundan
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

6.  Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.

Authors:  Yong-Mei Zhu; Pan-Pan Wang; Jin-Yan Huang; Yun-Shuo Chen; Bing Chen; Yu-Jun Dai; Han Yan; Yi Hu; Wen-Yan Cheng; Ting-Ting Ma; Sai-Juan Chen; Yang Shen
Journal:  J Transl Med       Date:  2017-08-22       Impact factor: 5.531

7.  A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy.

Authors:  Ayda Bennour; Ikram Tabka; Yosra Ben Youssef; Zahra Kmeira; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Cancer Biol Med       Date:  2013-03       Impact factor: 4.248

8.  Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression.

Authors:  Jun Gu; Keyur P Patel; Bing Bai; Ching-Hua Liu; Guilin Tang; Hagop M Kantarjian; Zhenya Tang; Ronald Abraham; Rajyalakshmi Luthra; L Jeffrey Medeiros; Pei Lin; Xinyan Lu
Journal:  Mol Cytogenet       Date:  2015-08-19       Impact factor: 2.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.